Biohaven

Showing 4 posts of 4 posts found.

4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

July 26, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biohaven, FDA, Lyrica, NICE, Pfizer, UK, US, pharma, top ten

At the end of a week that could certainly be called “eventful” here in the UK – one that saw …

biohaven_enrolls_first_patient_in-97b6e9e792e571e7c1572873932fc7c0

FDA knocks back Biohaven’s ALS drug over manufacturing concerns

July 22, 2019
Sales and Marketing Biohaven, FDA, Nurtec, amyotrophic lateral sclerosis, pharma

Biohaven Pharmaceutical has seen its new therapy formulation for the treatment of amyotrophic lateral sclerosis (ALS) rejected by the FDA, …

neurons-3743011_960_720

Biohaven’s CGPR antagonist migraine treatment beats placebo in Phase 3 trial

July 11, 2019
Research and Development Biohaven, CGPR, clinical trials, headache, migraine, pharma

Connecticut-based firm Biohaven has said its migraine drug rimegepant showed superiority over placebo in a Phase 3 clinical trial. The …

headache

Reaction mixed to Biohaven’s migraine drug results

March 27, 2018
Manufacturing and Production, Research and Development Allergan, Biohaven, CGRP, biotech, drugs, migraine, pharma, pharmaceutical

Biohaven is full of confidence in its lead drug, rimegepant, evidenced only a few weeks ago when it decided to …

Latest content